ArticleCancer medicine2026
Factors Associated With Risk Stratification and Overall Survival of Black South African Men With Non-Metastatic Prostate Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEmerging evidence indicates significantly poorer overall survival for men with metastatic prostate cancer in resource-limited settings than in high-income countries. However, there is less understanding of the overall survival of non-metastatic disease, which could inform early treatment strategies.
objectiveTo prospectively examine factors associated with the National Comprehensive Cancer Network (NCCN) risk stratification and overall survival in 741 Black South African men with non-metastatic prostate cancer, some of whom also had co-morbidities (≥ 2 other chronic conditions).
methodsBaseline data on social and health factors were collected. Follow-up of participants monitored overall survival over a median of 4.3 (3.5-5.0) years. We used multivariable proportional ordinal regression to examine factors associated with non-metastatic prostate cancer risk stratification. Kaplan-Meier, Cox proportional hazards regression, and Pohar-Perme methods were used to calculate overall survival and assess associations.
resultsOur findings showed a generally favourable prognosis of non-metastatic prostate cancer with a 5-year overall survival of 79.0% (75.6-82.6) while the 5-year age-standardised net survival was 91.0% (95% CI 86.0-97.0). Overall survival differed significantly by the different NCCN risk groups, emerging early and widening over time, with the lowest survival in the high-risk groups. Only older age at diagnosis (Hazard Ratio per one-year increase:1.05 (95% CI: 1.02-1.08)), diabetes (HR: 1.70 (95% CI: 1.08-2.67)), and depression (HR: 1.67 (95% CI: 1.09-2.57)) at study recruitment were associated with poorer overall survival. Furthermore, only older age at diagnosis (HR: 1.04 (95% CI: 1.02-1.07)) was associated with higher non-metastatic prostate cancer risk.
conclusionsThese findings emphasise the need to address early diagnosis and comorbidities in non-metastatic prostate cancer, which could improve overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.